MEASLES VACCINE DEVELOPMENT IN RHESUS MONKEY

恒河猴麻疹疫苗的开发

• 批准号: 7562139
• 负责人: Michael B. McChesney
• 金额: $ 8.2万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562139
• 关键词: Age-Months; Attenuated; Computer Retrieval of Information on Scientific Projects Database; DNA Vaccines; Disease; Funding; Grant; Institution; Life; Macaca mulatta; Maternal antibody; Measles; Measles Vaccine; Newborn Infant; Nucleoproteins; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Viral; prevent; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The live, attenuated measles vaccine is very effective, although maternal antibody prevents its administration prior to 6 months of age. We are investigating the ability of a DNA vaccine encoding the measles viral hemaglutinin, fusion and nucleoprotein to protect newborn infants from measles (disease).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 目的：活的，减弱的麻疹疫苗非常有效，尽管母体抗体可防止其6个月大之前的给药。我们正在研究编码麻疹病毒血谷蛋白，融合和核蛋白蛋白保护新生婴儿免受麻疹（疾病）的DNA疫苗的能力。